| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary target is the proton-coupled oligopeptide transporter 1 (PEPT1), a member of the SLC15A family that mediates the uptake of di- and tripeptides. D-Ala-Lys-AMCA is a specific substrate for PEPT1 and is transported into cells. Uptake can be competitively inhibited by PEPT1 substrates such as Gly-Sar, Gly-Gln, and Gly-Gly-Gly.
|
|---|---|
| ln Vitro |
D-Ala-Lys-AMCA (25, 50 and 150 μM, 3 hours) is transported to metastatic and Caco-2 cells [1]. D-Ala-Lys-AMCA (25 μM, 10 min) is absorbed by enterocyte content in all small intestine segments, although there is no complete fluorescent agent in the internal sample [2].
D-Ala-Lys-AMCA is a known PEPT1 substrate that emits blue fluorescence. It is transported into liver cancer cells and Caco-2 cells. Uptake can be competitively inhibited by PEPT1 substrates. The dye is used for characterizing PEPT1-specific substrates or inhibitors. |
| ln Vivo |
In vivo data for D-Ala-Lys-AMCA are limited. It is primarily used as an in vitro tool for studying PEPT1-mediated transport. The compound may be used for ex vivo uptake studies in intestinal tissue. No specific in vivo efficacy studies have been reported.
|
| Enzyme Assay |
Non-cell assays for D-Ala-Lys-AMCA include fluorescence-based uptake assays using PEPT1-expressing cells or membrane vesicles. The compound is incubated with cells or vesicles, and uptake is measured by fluorescence spectroscopy at excitation 390 nm and emission 480 nm.
|
| Cell Assay |
Cell-based assays use Caco-2 cells or hepatocarcinoma cell lines expressing PEPT1. Cells are incubated with D-Ala-Lys-AMCA (1-100 µM) for 15-60 minutes at 37°C. Uptake is measured by fluorescence microscopy or flow cytometry. Competitive inhibition is assessed by co-incubation with PEPT1 substrates.
|
| Animal Protocol |
In vivo studies with D-Ala-Lys-AMCA are limited. If conducted, a typical protocol would involve ex vivo uptake studies in murine small intestine. The compound is applied to intestinal segments, and uptake is measured by fluorescence microscopy.
|
| References |
|
| Molecular Formula |
C21H28N4O6
|
|---|---|
| Molecular Weight |
432.4702
|
| Exact Mass |
432.2
|
| CAS # |
375822-19-8
|
| Related CAS # |
D-Ala-Lys-AMCA hydrochloride;2703746-41-0;D-Ala-Lys-AMCA TFA
|
| PubChem CID |
101147902
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-2.4
|
| tPSA |
174
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
31
|
| Complexity |
737
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=C(C(=O)OC2=C1C=CC(=C2)N)CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@@H](C)N
|
| InChi Key |
JBMWHNASOBPJQQ-WBMJQRKESA-N
|
| InChi Code |
InChI=1S/C21H28N4O6/c1-11-14-7-6-13(23)9-17(14)31-21(30)15(11)10-18(26)24-8-4-3-5-16(20(28)29)25-19(27)12(2)22/h6-7,9,12,16H,3-5,8,10,22-23H2,1-2H3,(H,24,26)(H,25,27)(H,28,29)/t12-,16+/m1/s1
|
| Chemical Name |
(2S)-6-[[2-(7-amino-4-methyl-2-oxochromen-3-yl)acetyl]amino]-2-[[(2R)-2-aminopropanoyl]amino]hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3123 mL | 11.5615 mL | 23.1230 mL | |
| 5 mM | 0.4625 mL | 2.3123 mL | 4.6246 mL | |
| 10 mM | 0.2312 mL | 1.1561 mL | 2.3123 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.